Abstract
Current antipsychotic medications are efficacious for the positive symptoms of schizophrenia. However, there remains a significant unmet need for alternate strategies that could result in improved tolerability and/or efficacy for negative and cognitive symptoms. A growing body of research suggests that NMDA mediated neuronal activity is involved in the etiology of schizophrenia. Glycine binds to a modulatory glycineB strychnine-insensitive binding site on the NR1 subunit of the NMDA receptor complex and acts necessary co-agonist for activation of the NMDA receptor. Thus, several approaches have emerged aimed towards modulating this glycine binding site. To date, the glycineB site agonists glycine and D-serine, the partial agonist, D-cycloserine and the glycine reuptake inhibitor, sarcosine, have been shown to provide relief to schizophrenic patients. These clinical findings, combined with a growing body of preclinical literature, support the notion that enhancing synaptic glycineB activity leads to an increase in the effectiveness of normal glutamatergic signaling at the NMDA receptor complex and provides efficacy for schizophrenic patients. Accordingly, the present review examines the role of glycineB site modulation as a therapeutic approach for the treatment of schizophrenia.
Keywords: hallucinations, cognitive dysfunction, dopaminergic transmission, glutamate, nmda-receptor antagonists
Current Neuropharmacology
Title: Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Volume: 3 Issue: 1
Author(s): Gene G. Kinney and Cyrille Sur
Affiliation:
Keywords: hallucinations, cognitive dysfunction, dopaminergic transmission, glutamate, nmda-receptor antagonists
Abstract: Current antipsychotic medications are efficacious for the positive symptoms of schizophrenia. However, there remains a significant unmet need for alternate strategies that could result in improved tolerability and/or efficacy for negative and cognitive symptoms. A growing body of research suggests that NMDA mediated neuronal activity is involved in the etiology of schizophrenia. Glycine binds to a modulatory glycineB strychnine-insensitive binding site on the NR1 subunit of the NMDA receptor complex and acts necessary co-agonist for activation of the NMDA receptor. Thus, several approaches have emerged aimed towards modulating this glycine binding site. To date, the glycineB site agonists glycine and D-serine, the partial agonist, D-cycloserine and the glycine reuptake inhibitor, sarcosine, have been shown to provide relief to schizophrenic patients. These clinical findings, combined with a growing body of preclinical literature, support the notion that enhancing synaptic glycineB activity leads to an increase in the effectiveness of normal glutamatergic signaling at the NMDA receptor complex and provides efficacy for schizophrenic patients. Accordingly, the present review examines the role of glycineB site modulation as a therapeutic approach for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Kinney G. Gene and Sur Cyrille, Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia, Current Neuropharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570159052773387
DOI https://dx.doi.org/10.2174/1570159052773387 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
Current Medicinal Chemistry Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets Sepsis-induced Cardiomyopathy
Current Cardiology Reviews New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism
Current Pharmaceutical Design Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science Current Strategies for the Development of Novel Antipsychotic Drugs
Mini-Reviews in Medicinal Chemistry Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry